After a request for additional input from oncologists, practice administrators, payer representatives, and experts in physician payment and business analysis, ASCO has issued updated guidance on PCOP. With CMS’ Oncology Care Model set to end in 2021, the current draft of ASCO’s Community-based Oncology Medical Home model would be an option to take its place.
In 2014, the American Society of Clinical of Oncology (ASCO) released its first alternative payment model, Consolidated Payments for Oncology Care, aimed at reducing overall spending on cancer care (eg, by preventing unnecessary hospitalizations) and increasing revenue for oncologists. That original model also promised 10% raises to practices that scored high on quality-care measures, while those that fell short could be docked the same amount. ASCO promised limited financial risk under this model.1
That was followed in 2015 by the then-proposed Patient-Centered Oncology Payment (PCOP) model that promised a more flexible payment model to help oncology practices deliver the right care at the right price while holding the practices accountable for actually delivering that care.2
Now, after a request for additional input from oncologists, practice administrators, payer representatives, and experts in physician payment and business analysis, ASCO has issued updated guidance on PCOP. With CMS’ Oncology Care Model set to end in 2021, the current draft of ASCO’s Community-based Oncology Medical Home model would be an option to take its place, building on feedback from pilot programs and concerns that the first PCOP model was not specific enough.3 CMS has also proposed Oncology Care First to debut in 2021.
This new ASCO model “has requirements that practices have to follow in the way they deliver care, and this satisfies the concerns of payers,” said Jeffery Ward, MD, past chair of ASCO's Government Relations Committee and a contributor to PCOP. The update also has made clinical pathways a cornerstone of care delivery. ASCO hopes to deliver on the promises of PCOP using 3 approaches4: (1) improving the delivery and coordination of care, (2) developing a performance-based reimbursement system, (3) consistently delivering high-quality care.
"We're stewards of our patients' well-being, and ASCO's model reflects everything we have learned in over 50 years of work to advance patient care," ASCO President Howard A. "Skip" Burris III, MD, FACP, FASCO, stated.
ASCO projects PCOP could save up to 8% across the healthcare system.
1. Lowes R. New ASCO plan would boost oncologist revenue. Medscape website. medscape.com/viewarticle/824664. Published May 6, 2014. Accessed November 26, 2019.
2. Nelson R. ASCO unveils new model for oncology payments. Medscape website. medscape.com/viewarticle/845222. Published May 22, 2015. Accessed November 26, 2019.
3. Nelson R. ASCO updates its Patient-Centered Oncology Payment model. Medscape website. medscape.com/viewarticle/921820#vp_2. Published and accessed November 26, 2019.
4. ASCO. ASCO’s Patient-Centered Oncology Payment model (PCOP) supports higher quality, more affordable cancer care. ASCO website. practice.asco.org/billing-coding-reporting/macra-quality-payment-program/alternative-payment-models. Accessed November 26, 2019.
References
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More